The peptide position analysis identified additional lung cancer susceptibility amino acid positions, including HLA-DRβ1 position 30 and 11 (P<sub>omnibus</sub>=6.11×10<sup>-5</sup> and 6.91×10<sup>-5</sup>), HLA-DQa1 47 and 76 (P<sub>omnibus</sub>=3.96×10<sup>-4</sup> and 1.41×10<sup>-2</sup>) and HLA-A 152 (P<sub>omnibus</sub>=4.86×10<sup>-4</sup>).
Our data suggest that Livin/ML-IAP may be an excellent target antigen in immunotherapy for lung cancer and Livin7 peptide may serve as a potent peptide vaccine for HLA-A*2402(+)/Livin(+) lung cancer patients.
CTL induced by the modified 9-mer WT1 peptide killed the natural 9-mer WT1 peptide-pulsed CIR-A*2402 cells, primary leukemia cells with endogenous WT1 expression and lung cancer cell lines in a WT1-specific HLA-A*2402-restricted manner.